CARSGEN-B (02171) saw its shares climb 4.22% in the morning session, currently trading at HK$16.31, with a turnover of HK$7.3022 million.

Recently, according to an announcement on the company's official WeChat account, CARSGEN announced a clinical collaboration with Dispatch Bio, a biotechnology firm utilizing its first-in-class Flare platform to develop universal treatments for solid tumors. The collaboration plans to initiate a Phase I clinical trial in China by 2026.

This trial will evaluate the combined therapy DISP-11 in patients with solid tumors. The combination therapy consists of an investigational treatment developed using Dispatch's pioneering Flare platform, which includes its novel tumor-specific virus DV-10, used in conjunction with CARSGEN's BCMA-targeted autologous CAR-T cell product, SAIKEZE® (Zevor-cel injection).

SAIKEZE® has already received approval from China's National Medical Products Administration (NMPA) for the treatment of multiple myeloma.